SELLING OFFER
Seek co-innovation with global enterprises and governmental institutions
Early Diagnosis Platform for Lung Cancer
243 2023. 4. 25.
Summary
Population-based screening of stage 0–I lung cancer is crucial to save lives. We describe the development of a method for the detection of a CYFRA 21-1-autoantibody complex and CYFRA 21-1 in plasma samples. The CIC/CYFRA 21-1 ratio allows the detection of stage I–IV lung cancer with 75.0% sensitivity and 97.3% specificity.
Advantages and Innovations
- Can be used in combination with LDCT for lung cancer screening;
- Improve the diagnostic capacity of LDCT and reduce the false-positive rates;
- StageⅠ lung cancer detection rate dramatically increases;
- Improve the currently low 5-year survival rate.
Stage of Development
Description
Lung cancer is the most common cause of cancer-related deaths globally. Patients diagnosed at early-stage (0–I) have a higher survival rate than the metastasized stages (III–IV). Thus, there is great potential to reduce mortality by diagnosing lung cancer at stage 0~I through community screening. LDCT is a promising method, but it has a high false-positive rate. Therefore, a biomarker test that can be used in combination with LDCT for lung cancer screening to reduce false-positive rates is highly awaited. The present study evaluated the applicability of our lung cancer product to detect stage 0~IV lung cancer. our lung cancer product detects stage I, stage II, stage III, and stage IV cancers with the sensitivities of 77.5%, 78.1%, 67.4%, and 33.3%, respectively, at the specificity of 97.3%. These results indicate that our lung cancer product can be used in conjunction with LDCT to screen lung cancer.
- Early Diagnosis of Breast Cancer (Phase 0~2, w/ Blood);
- Lateral Flow Assay (4 Biomarkers Immunology test);
- Sensitivity & Specificity: 78% & 90%;
- Package: 48 tests/kit (Usage for 12 persons);
- Run Time: 1 hour, KR Patent.
Technology Keywords
Market Application Keywords
Sector Group
Type and Size of Client
Type and Role of Partner Sought
- Big sales company capable of selling lung cancer products
- Sales companies capable of selling LDT (Lab Development Test)
- A primary hospital that diagnoses lung cancer
Type of Partnership Considered
License Agreement
Services Agreement
Company
Internal Reference
Category
If interested, please press this button.
We will answer you soon.